Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.

被引：4

作者：

Piha-Paul, Sarina Anne

Sachdev, Jasgit C.

Barve, Minal A.

LoRusso, Patricia

Szmulewitz, Russell Zelig

Patel, Sapna Pradyuman

McKee, Mark D.

Wolff, Johannes E.

Hu, Beibei

Sood, Anjla

Chen, Xiaotian

Wilson, Sarah C.

O'Neil, Bert H.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] HonorHealth Res Inst TGen, Scottsdale, AZ USA

[3] Mary Crowley Canc Res Ctr, Dallas, TX USA

[4] Yale Canc Ctr, New Haven, CT USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] AbbVie Inc, N Chicago, IL USA

[7] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.2510

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2510

引用

页数：1

共 50 条

[31] A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug ( IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naive to Daratumumab (dara)
Kumar, Shaji K.
Cornell, Robert F.
Landgren, Ola
Ailawadhi, Sikander
Higgins, Jack P.
Willert, Erin K.
Waltzman, Roger
Lin, Jianchang
Zhang, Yuhong
Lublinsky, Anya R.
Dash, Ajeeta B.
Hanley, Michael
Manoharan, Divya
Leichter, Morgan
Ottinger, Sean
Labotka, Richard J.
Newcomb, John
Vorog, Alexander
BLOOD, 2019, 134
[32] CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
Hollebecque, A.
de Bono, J. S.
Salvagni, S.
Plummer, R.
Niccoli, P.
Capdevila, J.
Curigliano, G.
Moreno, V.
De Braud, F.
Lopez-Brea, M.
Martin-Romano, P.
Baudin, E.
Arias, M.
De Alvaro, J.
Parra-Palau, J.
Sanchez-Perez, T.
Aronchik, I.
Filvaroff, E.
Lamba, M.
Nikolova, Z.
ANNALS OF ONCOLOGY, 2020, 31 : S6 - S6
[33] First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.
Wang, Judy Sing-Zan
De Vita, Serena
Karlix, Janet L.
Cook, Carl
Littlewood, Gillian M.
Hattersley, Maureen M.
Moorthy, Ganesh
Edlund, Helena
Fabbri, Giulia
Sachsenmeier, Kris F.
Davison, Chris
Clark, Edwin
Moore, Kathleen N.
Bauer, Todd Michael
Ulahannan, Susanna Varkey
Patel, Manish R.
Hamilton, Erika Paige
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[34] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Seymour, John Francis
Davids, Matthew Steven
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Miller, Thomas P.
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary Ann
Huang, David C. S.
Darden, David E.
Gressick, Lori A.
Nolan, Cathy E.
Yang, Jianning
Busman, Todd A.
Graham, Alison M.
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[35] First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)
Seymour, John F.
Cheah, Chan Yoon
Parrondo, Ricardo
Thompson, Meghan C.
Stevens, Don A.
Lasica, Masa
Wang, Michael L.
Kumar, Abhijeet
Trotman, Judith
Alwan, Maan
Ding, Wei
By, Kunthel
Tariq, Bilal
Chen, Xiangmei
Fabre, Shannon
Paik, Jason
Agarwal, Amit
Tam, Constantine S.
BLOOD, 2023, 142
[36] First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Chandana, Sreenivasa R.
Choudhury, Noura J.
Dowlati, Afshin
Chiang, Anne C.
Garmezy, Benjamin
Kim, Joo-Hang
Byers, Lauren Averett
Ahn, Myung-Ju
Kim, Tae Min
Kim, Young-Chul
Han, Ji-Youn
Bar, Jair
Zha, Jiuhong
Henner, William
Robinson, Randy
Kohlhapp, Fred
Hingorani, Pooja
Papadopoulos, Kyriakos P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.
Shimizu, Toshio
Doi, Toshihiko
Kondo, Shunsuke
Takahashi, Hideaki
Yamamoto, Noboru
Sheldon-Waniga, Emily
Zhou, Xiaofei
Bahamon, Brittany
Li, Hongmei
Kuboki, Yasutoshi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[38] First-in-human study of AMG 820, a monoclonal anti-CSF-1R (c-fms) antibody, in patients (pts) with advanced solid tumors
Papadopoulos, Kyriakos
Gluck, Larry
Martin, Lainie P.
Olszanski, Anthony J.
Ngarmchamnanrith, Gateree
Rasmussen, Erik
Amore, Benny
Nagorsen, Dirk
Hill, John S.
Stephenson, Joe
CANCER RESEARCH, 2016, 76
[39] Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)
Levis, Mark J.
Perl, Alexander E.
Altman, Jessica K.
Cortes, Jorge E.
Ritchie, Ellen K.
Larson, Richard A.
Smith, Catherine Choy
Wang, Eunice S.
Strickland, Stephen Anthony
Baer, Maria R.
Litzow, Mark Robert
Claxton, David
Schiller, Gary J.
Ustun, Celalettin
Liu, Charles
Gill, Stan
Sargent, Briana
Bahceci, Erkut
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.
Sangha, Randeep S.
Jamal, Rahima
Spratlin, Jennifer L.
Kuruvilla, John
Sehn, Laurie Helen
Weickert, Michael
Berthiaume, Luc G.
Mackey, John Robert
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →